RPH-2823 is a potent and selective inhibitor of the kinase enzyme TTK (also known as MPS1), which plays a critical role in the spindle assembly checkpoint during cell division. By inhibiting TTK, RPH-2823 disrupts proper chromosome segregation, leading to mitotic catastrophe and apoptosis in rapidly dividing cells, particularly cancer cells. This makes it a promising candidate for anticancer therapy, especially in tumors with chromosomal instability.

It has shown preclinical activity in various solid tumor models, including ovarian, breast, and lung cancers. RPH-2823 is being investigated for its ability to enhance the efficacy of other antimitotic agents and to overcome resistance to conventional chemotherapy. Its selectivity helps reduce off-target effects, improving the therapeutic window. Research is ongoing to evaluate its potential in combination therapies and its utility as a tool compound in studying mitotic mechanisms.